Business Context and Reporting Period
Company: Daxor Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Daxor is a medical device manufacturer focused on the BVA-100 Blood Volume Analyzer and its associated Volumex diagnostic kits. Through its wholly-owned subsidiary, Scientific Medical Systems (including the Idant division), the company provides cryobanking services for blood and semen. The company operates with a significant investment portfolio, primarily in utility stocks, which generates income to offset operating losses.
Key Financial Metrics
| Metric | 2005 | 2004 (Restated) | 2003 (Restated) |
|---|---|---|---|
| Operating Revenues | $1,343,538 | $1,066,315 | $1,013,647 |
| Total Costs & Expenses | $6,258,731 | $4,608,181 | $4,093,042 |
| Loss from Operations | $(4,915,193) | $(3,541,866) | $(3,079,395) |
| Total Other Income (Investments) | $3,579,212 | $3,152,244 | $2,184,528 |
| Net Loss | $(1,335,981) | $(389,622) | $(894,867) |
| Net Loss Per Share | $(0.29) | $(0.08) | $(0.19) |
| Total Assets | $59,565,053 | $56,041,322 | $48,439,875 |
| Total Liabilities | $20,820,252 | $15,788,034 | $11,841,383 |
| Stockholders' Equity | $38,744,801 | $40,253,288 | $36,598,492 |
| Investment Portfolio Value | $57,246,006 | $54,806,400 | $47,399,159 |
Note: 2004 and 2003 figures have been restated due to changes in accounting principles regarding revenue recognition, equipment capitalization, and mark-to-market valuation of derivatives.
Material Changes vs. Prior Period
- Operating Loss Expansion: The operating loss increased significantly to $4.92 million in 2005 from $3.54 million in 2004. This was driven by increased R&D expenses (upgrading the BVA-100 to a Windows-based system) and expanded marketing efforts.
- Revenue Growth: Operating revenues grew 26% to $1.34 million. Kit sales increased 45% year-over-year, despite the sale of only one BVA-100 analyzer unit in 2005 (compared to four in 2004).
- Investment Income: Total investment income (dividends and gains) rose to $3.58 million, offsetting a portion of the operating loss. Dividend income increased 26% to $2.51 million.
- Debt Increase: Total liabilities rose to $20.8 million, primarily due to an increase in short-term margin debt and bank loans used to fund operations and investment activities.
- Accounting Restatements: The company restated 2003 and 2004 financials to correct errors in revenue recognition (shifting from cash to accrual for cryobanking), capitalization of loaned equipment, and mark-to-market accounting for short positions and options.
Guidance, Outlook, and Risks
- Product Development: The company completed a major overhaul of the BVA-100, transitioning from a DOS to a Windows-based system (BVA-100W) to improve usability and CLIA compliance. The company expects to obtain UL and CE marks for European marketing in the second quarter of 2006.
- Market Challenges: Sales of the BVA-100 were hindered in 2005 by a Medicare reimbursement error regarding the Volumex kit cost, which was not corrected for ten months. The company is actively working to resolve this and has signed seven trial agreements in Q4 2005.
- Strategic Focus: Management plans to focus primarily on the Blood Volume Analyzer and the new "Blood Optimization Program" (BOP), which combines blood volume measurement with frozen autologous blood banking. The company intends to increase operating revenues even if it results in increased short-term losses.
- Liquidity and Capital: The company maintains a large investment portfolio ($57.2 million) to fund operations. Management believes current liquidity is adequate for the next 2-4 years but acknowledges that raising additional capital may be difficult.
- Risk Factors:
- Investment Company Status: The SEC has inquired about whether the company's cash management activities constitute an "investment company." Management argues it qualifies for "Safe Harbor" exemptions as an operating company, but this remains a regulatory risk.
- Market Acceptance: The primary risk is the failure of the medical marketplace to accept the BVA-100 as a standard of care due to cost-effectiveness concerns and physician unfamiliarity with blood volume measurement.
- Internal Controls: The company disclosed insufficient internal personnel with GAAP expertise, leading to the restatements. A CPA was hired in late 2005 to oversee accounting.
Investor Verification Checklist
- Restatement Impact: Verify the full impact of the 2003-2004 restatements on historical trends and the stability of the new accounting policies.
- Medicare Reimbursement: Confirm the status of the Medicare reimbursement correction for Volumex kits and its effect on future hospital sales.
- Investment Policy Risk: Assess the risk of the company being reclassified as an investment company by the SEC, which could alter its regulatory obligations and tax status.
- Operating Cash Flow: Review the cash flow statement to ensure the company can sustain its high R&D and SG&A burn rate without depleting its investment portfolio.
- Customer Concentration: Note that two customers accounted for over 10% of sales in the prior fiscal year; verify if this concentration persists.